Andrea Tubaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3200787/publications.pdf

Version: 2024-02-01

147 papers 3,503 citations

236925 25 h-index 53 g-index

155 all docs

155 docs citations

155 times ranked 4012 citing authors

#	Article	IF	CITATIONS
1	Initial Experience and Evaluation of a Nomogram for Outcome Prediction in Management of Medium-sized (1–2 cm) Kidney Stones. European Urology Focus, 2022, 8, 276-282.	3.1	8
2	Contemporary management of benign uretero-enteric strictures after cystectomy: a systematic review. Minerva Urology and Nephrology, 2022, 73, .	2.5	2
3	Re: Giorgio Ivan Russo, Carmen Scandura, Marina Di Mauro, et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.01.002.	3.1	2
4	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
5	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. European Urology Focus, 2021, 7, 432-439.	3.1	5
6	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. European Urology Oncology, 2021, 4, 49-55.	5.4	9
7	Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. European Urology Focus. 2021. 7. 178-185.	3.1	2
8	Laparoscopic simple prostatectomy: a large single-center prospective cohort study. Minerva Urology and Nephrology, 2021, 73, 107-113.	2.5	9
9	A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned. Journal of Urology, 2021, 205, 1145-1152.	0.4	O
10	Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics, 2021, 10, 373.	3.7	18
11	Digital rectal examination and prostate biopsy at the time of COVID-19 outbreak: are there risks of contamination for the urologist?. Minerva Urology and Nephrology, 2021, 73, 268-269.	2,5	0
12	Urology practice during the COVID-19 vaccination campaign. Urologia, 2021, 88, 039156032110163.	0.7	0
13	Male Lower Urinary Tract Symptoms and Benign Prostatic Obstruction: What Do Patients Want?. European Urology, 2021, 79, 810-811.	1.9	O
14	Development of a nomogram predicting the probability of stone free rate in patients with ureteral stones eligible for semi-rigid primary laser uretero-litothripsy. World Journal of Urology, 2021, 39, 4267-4274.	2.2	9
15	Re: Mini Percutaneous Nephrolithotomy Is a Noninferior Modality to Standard Percutaneous Nephrolithotomy for the Management of 20–40 mm Renal Calculi: A Multicenter Randomized Controlled Trial. European Urology, 2021, 80, 114-115.	1.9	1
16	Transperineal Interstitial Laser Ablation of the Prostate, A Novel Option for Minimally Invasive Treatment of Benign Prostatic Obstruction. European Urology, 2021, 80, 673-674.	1.9	6
17	Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation. European Journal of Surgical Oncology, 2021, 47, 2640-2645.	1.0	6
18	Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. Minerva Urology and Nephrology, 2021, , .	2.5	3

#	Article	IF	CITATIONS
19	Ultrasound prostate parameters as predictors of successful trial without catheter after acute urinary retention in patients ongoing medical treatment for benign prostatic hyperplasia: a prospective multicenter study. Minerva Urology and Nephrology, 2021, 73, 625-630.	2.5	1
20	Impairment of autophagy may represent the molecular mechanism behind the relationship between obesity and inflammation in patients with BPH and LUTS. Minerva Urology and Nephrology, 2021, 73, 631-637.	2.5	7
21	Post-Operative Acute Urinary Retention After Greenlight Laser. Analysis Of Risk Factors from A Multicentric Database. Urology Journal, 2021, , .	0.4	3
22	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World Journal of Urology, 2020, 38, 151-158.	2.2	23
23	GreenLight Photoselective Vaporization of the Prostate: One Laser for Different Prostate Sizes. Journal of Endourology, 2020, 34, 54-62.	2.1	15
24	Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World Journal of Urology, 2020, 38, 1757-1764.	2.2	6
25	External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers. World Journal of Urology, 2020, 38, 2555-2561.	2.2	5
26	Radical penectomy, a compromise for life: results from the PECAD study. Translational Andrology and Urology, 2020, 9, 1306-1313.	1.4	9
27	Obesity and Prostate Cancer: The Tip of a High Mountain Still to Be Conquered. Journal of Clinical Medicine, 2020, 9, 2070.	2.4	3
28	How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?. Frontiers in Surgery, 2020, 7, 563006.	1.4	17
29	Impact of the COVIDâ€19 pandemic on urological practice in emergency departments in Italy. BJU International, 2020, 126, 245-247.	2.5	36
30	Risk of Virus Contamination Through Surgical Smoke During Minimally Invasive Surgery: A Systematic Review of the Literature on a Neglected Issue Revived in the COVID-19 Pandemic Era. European Urology Focus, 2020, 6, 1058-1069.	3.1	28
31	Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?. European Urology, 2020, 78, 786-811.	1.9	150
32	The role of bladder wall thickness in the evaluation of detrusor underactivity: Development of a clinical nomogram. Neurourology and Urodynamics, 2020, 39, 1115-1123.	1.5	14
33	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the) Tj ETQq1 I 2020, 72, 595-604.	l 0.784314 ı	gBT/Overlo
34	Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 622-628.	3.9	12
35	The urothelium, the urinary microbioma and men LUTS: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 712-722.	3.9	9
36	Urology practice during the COVID-19 pandemic. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 369-375.	3.9	195

#	Article	IF	Citations
37	Clinical pathways for urology patients during the COVID-19 pandemic. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 376-383.	3.9	80
38	The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 729-736.	3.9	4
39	Complications and quality of life of ileal conduit, orthotopic neobladder and ureterocutaneostomy: systematic review of reports using the Clavien-Dindo Classification. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 408-419.	3.9	15
40	Night shift workers refer higher urinary symptoms with an impairment quality of life: a single cohort study. Minerva Urology and Nephrology, 2020, , .	2.5	6
41	Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort. Minerva Urology and Nephrology, 2020, , .	2.5	0
42	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	2.5	1
43	Medical treatment for benign prostatic hyperplasia: Where do we stand?. Urologia, 2019, 86, 115-121.	0.7	4
44	The EORTC quality of life questionnaire predicts early and long-term incontinence in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 1006-1013.	1.6	8
45	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. Journal of Clinical Medicine, 2019, 8, 1126.	2.4	12
46	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE, 2019, 14, e0224151.	2.5	8
47	Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. Clinical Genitourinary Cancer, 2019, 17, 402-407.	1.9	33
48	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). Urology, 2019, 129, 139-145.	1.0	9
49	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq1 1 0.78	84 3.1 :4 rgB	T /20 verlock
50	Retroperitoneoscopy in urology: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 9-16.	3.9	10
51	Complex renal masses: partial or no partial nephrectomy?. Annals of Translational Medicine, 2019, 7, S312-S312.	1.7	3
52	Urinary Urgency: A Symptom In Need Of A Cure. Research and Reports in Urology, 2019, Volume 11, 327-331.	1.0	0
53	Is our current understanding and management of nocturia allowing improved care? International Consultation on Incontinenceâ€Research Society 2018. Neurourology and Urodynamics, 2019, 38, S127-S133.	1.5	3
54	Re: Association Between the Amount of Vaginal Mesh Used with Mesh Erosions and Repeated Surgery After Repairing Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 2019, 75, 196-197.	1.9	5

#	Article	lF	CITATIONS
55	Variations of Nighttime and Daytime Bladder Capacity in Patients with Nocturia: Implication for Diagnosis and Treatment. Journal of Urology, 2019, 201, 962-966.	0.4	13
56	The use of laser as a therapeutic modality as compared to TURP for the small prostate â‰ 4 0 mL: a collaborative review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 569-575.	3.9	26
57	Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study. Minerva Urology and Nephrology, 2019, , .	2.5	3
58	Ejaculation disorders in prostate surgery. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 549-550.	3.9	8
59	External validation of Imamura nomogram as a tool to predict preoperatively laser semi-rigid ureterolithotripsy outcomes. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 531-536.	3.9	7
60	Smoking reduces PSA accuracy for detection of prostate cancer: results from an Italian cross-sectional study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 583-589.	3.9	5
61	Repeat prostateâ€specific antigen (<scp>PSA</scp>) test before prostate biopsy: a 20% decrease in <scp>PSA</scp> values is associated with a reduced risk of cancer and particularly of highâ€grade cancer. BJU International, 2018, 122, 83-88.	2.5	9
62	Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy. European Urology, 2018, 73, 980-981.	1.9	1
63	EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. European Urology, 2018, 73, 596-609.	1.9	237
64	The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. European Journal of Surgical Oncology, 2018, 44, 835-839.	1.0	27
65	Standard vs. anatomical 180-W GreenLight laser photoselective vaporization of the prostate: a propensity score analysis. World Journal of Urology, 2018, 36, 91-97.	2.2	9
66	Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement. Neurourology and Urodynamics, 2018, 37, 904-915.	1.5	6
67	Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement. Prostate Cancer and Prostatic Diseases, 2018, 21, 287-292.	3.9	16
68	Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 570-578.	3.9	10
69	Young Academic Urologists' benign prostatic obstruction nomogram predicts clinical outcome in patients treated with transurethral resection of prostate: an Italian cohort study. Minerva Urology and Nephrology, 2018, 70, 211-217.	2.5	14
70	Expert Opinion on Three Clinical Cases with a Common Urgent Problem: Urge Urinary Incontinence. Case Reports in Urology, 2018, 2018, 1-6.	0.3	1
71	Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis. Urology, 2018, 121, 147-152.	1.0	14
72	Erectile Dysfunction and Lower Urinary Tract Symptoms. Current Urology Reports, 2018, 19, 61.	2.2	11

#	Article	IF	CITATIONS
73	Bladder stone management: an update. Minerva Urology and Nephrology, 2018, 70, 53-65.	2.5	15
74	Castration-resistance prostate cancer: what is in the pipeline?. Minerva Urology and Nephrology, 2018, 70, 22-41.	2.5	17
75	An update on prostate biopsy in the era of magnetic resonance imaging. Minerva Urology and Nephrology, 2018, 70, 264-274.	2.5	19
76	Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients $\hat{a} \in \mathbb{R}^{M}$ care $\hat{a} \in \mathbb{R}^{M}$ a systematic review. BMC Urology, 2018, 18, 62.	1.4	28
77	Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review. Current Urology Reports, 2018, 19, 70.	2.2	8
78	Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 347-360.	3.9	17
79	Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory) Tj ETQq $1\ 1$	0.784314 rgBT 0.5	/8verlock 1
80	Exercise to prevent lower urinary tract symptoms: myth and reality. BJU International, 2018, 122, 170-170.	2.5	1
81	Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer and Prostatic Diseases, 2018, 21, 438-445.	3.9	14
82	External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 364.e1-364.e7.	1.6	13
83	Cigarette smoking is not associated with prostate cancer diagnosis and aggressiveness: a cross sectional Italian study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 598-605.	3.9	13
84	Moderate-to-high cardiovascular risk is associated with increased lower urinary tract storage symptoms in patients with benign prostatic enlargement. Minerva Urology and Nephrology, 2018, 70, 340-346.	2.5	4
85	Dutasteride addâ€on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alphaâ€odrenergic antagonist monotherapy: A single center prospective study. Neurourology and Urodynamics, 2017, 36, 2096-2100.	1.5	4
86	Metabolic Syndrome Does Not Increase the Risk of Ejaculatory Dysfunction in Patients With Lower Urinary Tract Symptoms and Benign Prostatic Enlargement: An Italian Single-center Cohort Study. Urology, 2017, 105, 85-90.	1.0	8
87	Can a patient reported outcome be adequate without assessing quality of life in lower urinary tract dysfunction?. Neurourology and Urodynamics, 2017, 36, 943-948.	1.5	O
88	Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urology, 2017, 17, 22.	1.4	32
89	Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?. Current Urology Reports, 2017, 18, 72.	2.2	9
90	Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Therapeutic Advances in Urology, 2017, 9, 137-154.	2.0	43

#	Article	IF	Citations
91	Detrusor overactivity increases bladder wall thickness in male patients: A urodynamic multicenter cohort study. Neurourology and Urodynamics, 2017, 36, 1616-1621.	1.5	8
92	Non-invasive ultrasound measurements in male patients with LUTS and benign prostatic obstruction: implication for diagnosis and treatment. Minerva Urology and Nephrology, 2017, 69, 220-233.	2.5	7
93	New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urology and Nephrology, 2017, 69, 119-132.	2.5	9
94	The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late?. Minerva Urology and Nephrology, 2017, 69, 242-252.	2.5	12
95	Basic methods for the assessment of health-related quality of life in uro-oncological patients. Minerva Urology and Nephrology, 2017, 69, 409-420.	2.5	6
96	Green light vaporization of the prostate: is it an adult technique?. Minerva Urology and Nephrology, 2017, 69, 109-118.	2.5	12
97	Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget, 2017, 8, 50904-50910.	1.8	13
98	Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre crossâ€sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU International, 2016, 117, 867-873.	2.5	23
99	Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Neurourology and Urodynamics, 2016, 35, 278-282.	1.5	19
100	Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer, 2016, 16, 407.	2.6	24
101	Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Reviews Urology, 2016, 13, 613-626.	3.8	155
102	The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery. Current Urology Reports, 2016, 17, 61.	2.2	18
103	Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology, 2016, 96, 165-170.	1.0	21
104	Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. BJU International, 2016, 117, E29-35.	2.5	33
105	Grey Zone: Urinary Incontinence. European Urology Focus, 2016, 2, 337-338.	3.1	2
106	Tamsulosin or Silodosin Adjuvant Treatment Is Ineffective in Improving Shockwave Lithotripsy Outcome: A Short-Term Follow-Up Randomized, Placebo-Controlled Study. Journal of Endourology, 2016, 30, 817-821.	2.1	14
107	The diagnosis of benign prostatic obstruction: Development of a clinical nomogram. Neurourology and Urodynamics, 2016, 35, 235-240.	1.5	19
108	A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. European Urology, 2016, 69, 94-102.	1.9	201

#	Article	IF	CITATIONS
109	Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?. BMC Urology, 2015, 15, 96.	1.4	63
110	A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU International, 2015, 116, 853-861.	2.5	35
111	Editorial Comment from Dr Presicce <i>etÂal</i> . to Emerging links between nonâ€neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. International Journal of Urology, 2015, 22, 992-992.	1.0	0
112	The Evolving Picture of Lower Urinary Tract Symptom Management. European Urology, 2015, 67, 271-272.	1.9	12
113	Innovations in medical and surgical treatment. Nature Reviews Urology, 2015, 12, 76-78.	3.8	5
114	Central obesity is predictive of persistent storage lower urinary tract symptoms (<scp>LUTS</scp>) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU International, 2015, 116, 271-277.	2.5	37
115	Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. European Urology, 2015, 68, 418-425.	1.9	147
116	Re: Association Between Metabolic Syndrome and Severity of Lower Urinary Tract Symptoms: An Observational Study in a 4666 European Men Cohort. European Urology, 2015, 67, 973-974.	1.9	1
117	Re: Christian Gratzke, Alexander Bachmann, Aurelien Descazeaud, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol 2015;67:1099–109 European Urology, 2015, 68, e15.	1.9	3
118	Patients With Prostatic Inflammation Undergoing Transurethral Prostatic Resection Have a Larger Early Improvement of Storage Symptoms. Urology, 2015, 86, 359-367.	1.0	17
119	Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1–pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors?. European Urology, 2015, 67, 943-951.	1.9	45
120	The Diagnosis of Benign Prostatic Obstruction: Validation of the Young Academic Urologist Clinical Nomogram. Urology, 2015, 86, 1032-1036.	1.0	12
121	The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 2015, 18, 376-386.	0.3	12
122	A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. Journal of Urology, 2015, 193, 570-578.	0.4	117
123	The management of overactive bladder. Current Opinion in Urology, 2015, 25, 305-310.	1.8	28
124	Quality of Life and Sexual Health in the Aging of PCa Survivors. International Journal of Endocrinology, 2014, 2014, 1-16.	1.5	13
125	180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial—The GOLIATH Study. European Urology, 2014, 65, 931-942.	1.9	189
126	Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: A prospective single cohort study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 28.e27-28.e31.	1.6	6

#	Article	IF	CITATIONS
127	Serum levels of $17 \cdot \hat{l}^2$ -estradiol are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e9-35.e13.	1.6	2
128	Do Young Patients with Renal Cell Carcinoma Feature a Distinct Outcome after Surgery? A Comparative Analysis of Patient Age Based on the Multinational CORONA Database. Journal of Urology, 2014, 191, 310-315.	0.4	20
129	Metabolic Syndrome and Lower Urinary Tract Symptoms in Patients With Benign Prostatic Enlargement: A Possible Link to Storage Symptoms. Urology, 2014, 84, 1181-1187.	1.0	50
130	Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life1Matthias May and Luca Cindolo have equally contributed to first authorship.2Sabine Brookman-May and Petros Sountoulides have equally contributed to last authorship Urologic Oncology: Seminars and Original Investigations, 2014, 32,	1.6	8
131	1252-1258. Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: Results from an Italian biopsy cohort. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 80-84.	1.6	11
132	Metabolic Syndrome, Obesity, and Radical Cystectomy Complications: A Clavien Classification System-Based Analysis. Clinical Genitourinary Cancer, 2014, 12, 384-393.	1.9	18
133	Re: Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. European Urology, 2014, 65, 1220-1221.	1.9	0
134	The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports, 2013, 8, 142-149.	0.5	13
135	Re: Safety and Feasibility of the Prostatic Urethral Lift: A Novel, Minimally Invasive Treatment for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). European Urology, 2011, 60, 1120-1121.	1.9	5
136	Ultrasound imaging of the pelvic floor: Where are we going?. Neurourology and Urodynamics, 2011, 30, 729-734.	1.5	14
137	Bladder weight and detrusor thickness as parameters of progression of benign prostatic hyperplasia. Current Opinion in Urology, 2010, 20, 37-42.	1.8	18
138	Reduction of Prostate-specific Antigen After Tamsulosin Treatment in Patients With Elevated Prostate-specific Antigen and Lower Urinary Tract Symptoms Associated With Low Incidence of Prostate Cancer at Biopsy. Urology, 2010, 76, 436-441.	1.0	9
139	The Electromagnetic Detection of Prostatic Cancer: Evaluation of Diagnostic Accuracy. Urology, 2008, 72, 340-344.	1.0	17
140	Transurethral needle ablation of the prostate. Current Opinion in Urology, 2007, 17, 7-11.	1.8	3
141	Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder. European Urology, 2007, 52, 1204-1212.	1.9	222
142	Overactive bladder: epidemiology and social impact. Current Opinion in Obstetrics and Gynecology, 2005, 17, 507-511.	2.0	34
143	The effect of bladder outlet obstruction treatment on ultrasound-determined bladder wall thickness. Reviews in Urology, 2005, 7 Suppl 6, S35-42.	0.9	7
144	The Relation of Lower Urinary Tract Symptoms with Life-Style Factors and Objective Measures of Benign Prostatic Enlargement and Obstruction: An Italian Survey. European Urology, 2004, 45, 767-772.	1.9	32

Andrea Tubaro

#	Article	IF	CITATIONS
145	Defining overactive bladder: Epidemiology and burden of disease. Urology, 2004, 64, 2-6.	1.0	156
146	Early Treatment of Benign Prostatic Hyperplasia. Drugs and Aging, 2003, 20, 185-195.	2.7	12
147	Investigation of benign prostatic hyperplasia. Current Opinion in Urology, 2003, 13, 17-22.	1.8	7